ReviewMolecular therapy. Nucleic acids2026
Meta-analysis of adverse events in clinical studies with antisense oligonucleotide therapies.
Review in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisense oligonucleotides (ASOs) are increasingly being used as a platform to target various diseases. Currently, there are 13 USFDA- or EMA-approved ASO therapies. Adverse events resulting from ASO treatments are assessed on a per drug basis, but for many ongoing ASO developments targeting N-of-1 mutations, conventional randomized clinical trials to assess safety cannot be performed. Here, we conducted a systematic review and meta-analysis of adverse events in clinical studies conducting trials of ASO therapies. The study aims to provide better insight into the safety aspects of ASO design choices and to summarize knowledge of the safety aspects of ASOs so that we can better inform researchers and physicians of possible adverse events that can occur during (N-of-1) ASO treatments. Our results provide a list of common adverse events and event rates obtained from pooled data from both approved and non-approved ASO drugs, and we include recommendations that can provide insights into the nature of ASO-induced adverse events in future trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.